Evidence map›Paper›PMID 30222631›Full record

Trial reportCritical care medicine2018

Vitamin D to Prevent Lung Injury Following Esophagectomy-A Randomized, Placebo-Controlled Trial.

Dhruv Parekh, Rachel C A Dancer, Aaron Scott, Vijay K D'Souza, Phillip A Howells, Rahul Y Mahida, Jonathan C Y Tang, Mark S Cooper, William D Fraser, LamChin Tan and 5 more

Open access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Critical care medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 5 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 5 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Observational
  11. Observational
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Dhruv ParekhWarwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, United Kingdom.
Rachel C A DancerBirmingham Acute Care Research Group, Institute of Inflammation and Aging, University of Birmingham, Birmingham, United Kingdom.
Aaron ScottBirmingham Acute Care Research Group, Institute of Inflammation and Aging, University of Birmingham, Birmingham, United Kingdom.
Vijay K D'SouzaBirmingham Acute Care Research Group, Institute of Inflammation and Aging, University of Birmingham, Birmingham, United Kingdom.
Phillip A HowellsBirmingham Acute Care Research Group, Institute of Inflammation and Aging, University of Birmingham, Birmingham, United Kingdom.
Rahul Y MahidaBirmingham Acute Care Research Group, Institute of Inflammation and Aging, University of Birmingham, Birmingham, United Kingdom.
Jonathan C Y TangNorwich Medical School, University of East Anglia, Norwich, United Kingdom.
Mark S CooperDiscipline of Medicine, Concord Clinical School, University of Sydney, NSW, Australia.
William D FraserNorwich Medical School, University of East Anglia, Norwich, United Kingdom.
LamChin TanUniversity Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom.
Fang GaoBirmingham Acute Care Research Group, Institute of Inflammation and Aging, University of Birmingham, Birmingham, United Kingdom.
Adrian R MartineauBlizard Institute, Queen Mary University of London, London, United Kingdom.
Olga TuckerBirmingham Acute Care Research Group, Institute of Inflammation and Aging, University of Birmingham, Birmingham, United Kingdom.
Gavin D PerkinsWarwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, United Kingdom.
David R ThickettBirmingham Acute Care Research Group, Institute of Inflammation and Aging, University of Birmingham, Birmingham, United Kingdom.
University of Birmingham · GBUniversity of East Anglia · GBQueen Mary University of London · GBUniversity Hospitals Coventry and Warwickshire NHS Trust · GBUniversity of Warwick · GB

Funding

Medical Research Council G0701603Medical Research Council G1100196Medical Research Council MR/J011266/1Medical Research Council MR/L002736/1Medical Research Council MR/N021185/1
6 · The paper itself

Abstract

objectivesObservational studies suggest an association between vitamin D deficiency and adverse outcomes of critical illness and identify it as a potential risk factor for the development of lung injury. To determine whether preoperative administration of oral high-dose cholecalciferol ameliorates early acute lung injury postoperatively in adults undergoing elective esophagectomy.

designA double-blind, randomized, placebo-controlled trial.

settingThree large U.K. university hospitals. PATIENTS: Seventy-nine adult patients undergoing elective esophagectomy were randomized.

interventionsA single oral preoperative (3-14 d) dose of 7.5 mg (300,000 IU; 15 mL) cholecalciferol or matched placebo. MEASUREMENTS AND MAIN

resultsPrimary outcome was change in extravascular lung water index at the end of esophagectomy. Secondary outcomes included PaO2:FIO2 ratio, development of lung injury, ventilator and organ-failure free days, 28 and 90 day survival, safety of cholecalciferol supplementation, plasma vitamin D status (25(OH)D, 1,25(OH)2D, and vitamin D-binding protein), pulmonary vascular permeability index, and extravascular lung water index day 1 postoperatively. An exploratory study measured biomarkers of alveolar-capillary inflammation and injury. Forty patients were randomized to cholecalciferol and 39 to placebo. There was no significant change in extravascular lung water index at the end of the operation between treatment groups (placebo median 1.0 [interquartile range, 0.4-1.8] vs cholecalciferol median 0.4 mL/kg [interquartile range, 0.4-1.2 mL/kg]; p = 0.059). Median pulmonary vascular permeability index values were significantly lower in the cholecalciferol treatment group (placebo 0.4 [interquartile range, 0-0.7] vs cholecalciferol 0.1 [interquartile range, -0.15 to -0.35]; p = 0.027). Cholecalciferol treatment effectively increased 25(OH)D concentrations, but surgery resulted in a decrease in 25(OH)D concentrations at day 3 in both arms. There was no difference in clinical outcomes.

conclusionsHigh-dose preoperative treatment with oral cholecalciferol was effective at increasing 25(OH)D concentrations and reduced changes in postoperative pulmonary vascular permeability index, but not extravascular lung water index.

Indexed as

Acute Lung InjuryAgedBiomarkersCholecalciferolDietary SupplementsDose-Response Relationship, DrugDouble-Blind MethodEsophagectomyExtravascular Lung WaterFemaleHospitals, UniversityHumansMaleMiddle AgedRespiratory Function TestsUnited KingdomBiomarkersCholecalciferolVitamin D

Identifiers

PMID30222631
PMCPMC6250246
OpenAlexW2895294819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.